Steven Cohen Liquidia Corp Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$6.63 - $9.9 $13,637 - $20,364	2,057 New	2,057 $16,000
Q2 2022 Aug 15, 2022	SELL	$3.37 - $7.55 $782,436 - $1.75 Million	-232,177 Reduced 82.28%	50,000 $218,000
Q1 2022 May 16, 2022	BUY	$5.14 - $7.38 $1.45 Million - $2.08 Million	282,177 New	282,177 $2.03 Million
Q3 2020 Nov 16, 2020	SELL	$4.34 - $8.28 $217,000 - $413,999	-50,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$4.86 - $11.44 $243,000 - $572,000	50,000 New	50,000 $421,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.